MedAI newsletter

Archives
Log in
Subscribe
November 12, 2026

MedAI Update: Thursday, November 12, 2026

MedAI Update: Daily Digest, Thursday, November 12, 2026 AI in medicine policy, explained. Five stories a day, each summarized in plain language.

PART 1: QUICK SUMMARY 1. Japan Regulates Most Medical AI as Software Under Existing Device Law 2. Medical Association Says AI Can Support Care but Cannot Be Licensed as a Professional 3. CMS Sets Medicare Payment Path for Software-Based Diagnostic Tools 4. Medical Groups Seek Rules on Liability When Clinical AI Causes Harm 5. EU Sandbox Rules Offer Testing Records but Not Market Clearance

PART 2: THE DETAILS

Japan Regulates Most Medical AI as Software Under Existing Device Law Source: https://www.asianhhm.com/articles/ai-healthcare-regulations-in-japan Japan treats most diagnostic and treatment AI as regulated medical software under its PMD Act rather than a separate AI law. A 2013 amendment that took effect in November 2014 brought software that is not a physical object into the medical device category, creating a path for software as a medical device. Why it matters: The framework shapes how AI tools can reach hospitals, but the provided text is cut off before full details on review, evidence, and generative AI.

Medical Association Says AI Can Support Care but Cannot Be Licensed as a Professional Source: https://www.ama-assn.org/press-center/ama-press-releases/ama-artificial-intelligence-can-augment-physicians-don-t-call-it The American Medical Association says AI tools can help improve healthcare, while a new policy clarifies boundaries around the technology. The group states that AI cannot be licensed in the role reserved for a medical professional. Why it matters: Clear scope limits matter as AI enters care, but the provided text mostly contains navigation and does not give the policy's full details.

CMS Sets Medicare Payment Path for Software-Based Diagnostic Tools Source: https://insights.citeline.com/medtech-insight/medtech-insight/policy-and-regulation/regulation/cms-revises-remote-monitoring-payments-sets-medicare-rates-for-14-software-based-diagnostic-tools-XISSZUGRQ5GVHOFNHASBYEIXDE/ The 2027 Medicare fee schedule final rule changes payment for remote monitoring and sets Medicare rates for 14 software-based diagnostic analyses. It also creates a payment framework for certain software-based diagnostic tools, including AI-enabled pathology and oncology applications, and updates reimbursement for technologies such as fluorescence wound imaging. Why it matters: Payment rules influence whether AI diagnostics are adopted, but the provided text does not list the actual rates or full laboratory payment changes.

Medical Groups Seek Rules on Liability When Clinical AI Causes Harm Source: https://www.medscape.com/viewarticle/whos-responsible-when-clinical-ai-harms-doc-groups-weigh-2026a100175x Medical organizations are beginning to recommend how lawmakers, courts, and regulators should assign responsibility when clinical AI is used and a patient is harmed. The American Medical Association has proposed liability protections for users of clinical AI and told the FDA that AI developers should bear the burden of making AI-assisted medical devices work properly. Why it matters: As AI use grows, unclear liability could affect adoption and accountability, and the text says court outcomes are still unknown.

EU Sandbox Rules Offer Testing Records but Not Market Clearance Source: https://www.techtimes.com/articles/330540/20261112/eu-ai-regulatory-sandbox-rules-start-december-1-tests-earn-no-compliance-clearance-liability-stays.htm The European Commission adopted common rules for national AI regulatory sandboxes under the EU AI Act, taking effect on December 1. Participants receive written proof and an exit report, but these do not grant conformity status or remove liability for third-party damage or compliance with EU law. Why it matters: The rules clarify what sandbox testing does and does not provide, which matters for companies deciding whether to test AI in Europe before market approval.

This newsletter is information, not medical advice.

Subscribe to get this digest each morning: https://buttondown.com/vote

Don't miss what's next. Subscribe to MedAI newsletter :
← Newer MedAI Update: Friday, November 13, 2026 Older → MedAI Update: Wednesday, November 11, 2026
Powered by Buttondown, the easiest way to start and grow your newsletter.